These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 34694649)

  • 1. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
    Massaro F; Pavone V; Stefani PM; Botto B; Pulsoni A; Patti C; Cantonetti M; Visentin A; Scalzulli PR; Rossi A; Galimberti S; Cimminiello M; Gini G; Musso M; Sorio M; Arcari A; Zilioli VR; Luppi M; Mannina D; Fabbri A; Pietrantuono G; Annibali O; Tafuri A; Prete E; Mulè A; Barbolini E; Marcheselli L; Luminari S; Merli F
    Hematol Oncol; 2022 Feb; 40(1):31-39. PubMed ID: 34694649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab vedotin consolidation therapy after autologous stem-cell transplantation in patients with high-risk Hodgkin lymphoma: Multicenter retrospective study.
    Akay OM; Ozbalak M; Pehlivan M; Yildiz B; Uzay A; Yigenoglu TN; Elverdi T; Kaynar L; Ayyildiz O; Yonal Hindilerden I; Goksoy HS; Izmir Guner S; Gunes AK; Sonmez M; Kurt Yuksel M; Civriz Bozdag S; Ozkurt ZN; Toptas T; Dogu MH; Salim O; Saydam G; Yavasoglu I; Ayli M; Ozet G; Albayrak M; Birtas Atesoglu E; Toprak SK; Yildirim R; Mehtap O; Kalayoglu Besisik S; Nalcaci M; Altuntas F; Ferhanoglu B
    Hematol Oncol; 2021 Oct; 39(4):498-505. PubMed ID: 34171130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma.
    Martínez C; de Haro ME; Romero S; Gutiérrez A; Domingo-Domènech E; González-Rodríguez AP; Zeberio I; Martínez-Badas MP; Rodríguez-Izquierdo A; Carpio C; Bastos-Oreiro M; Hernández-Rivas JÁ; Vallansot R; Kelleher N; Díaz-Gálvez FJ; Torrado T; Pereira A; García-Sanz R;
    Ann Hematol; 2023 Feb; 102(2):429-437. PubMed ID: 36370191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI; Szabó R; Illés Á; Földeák D; Piukovics K; Szomor Á; Gopcsa L; Miltényi Z
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
    Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
    Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival outcomes of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
    Wang Z; Sun K; Zhu ZM; Zhang P; Yang J; Yang SW; Zheng MQ
    Eur Rev Med Pharmacol Sci; 2021 Apr; 25(7):2941-2948. PubMed ID: 33877657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
    Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
    Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed/refractory classic Hodgkin lymphoma.
    Desai SH; Spinner MA; David K; Bachanova V; Goyal G; Kahl B; Dorritie K; Azzi J; Kenkre VP; Arai S; Chang C; Fusco B; Sumransub N; Hatic H; Saba R; Ibrahim U; Harris EI; Shah H; Murphy J; Ansell S; Jagadish D; Orellana-Noia V; Diefenbach C; Iyenger S; Rappazzo KC; Mishra R; Choi Y; Nowakowski GS; Advani RH; Micallef IN
    Am J Hematol; 2023 Mar; 98(3):464-471. PubMed ID: 36629030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes Related to FDG-PET-CT Response in Patients With Hodgkin Lymphoma Treated With Brentuximab-Vedotin at Relapse or Consolidation.
    Kedmi M; Khaustov P; Ribakovsy E; Benjamini O; Avigdor A
    Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e929-e937. PubMed ID: 34366266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brentuximab Vedotin as Consolidation Therapy After Autologous Stem Cell Transplantation in Children and Adolescents (<18 y) With Early Relapse Hodgkin Lymphoma.
    Fernández KS; Mavers M; Marks LJ; Agarwal R
    J Pediatr Hematol Oncol; 2021 Mar; 43(2):e191-e194. PubMed ID: 31876780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Gianni AM; Carella A; Osmanov D; Bachanova V; Sweetenham J; Sureda A; Huebner D; Sievers EL; Chi A; Larsen EK; Hunder NN; Walewski J;
    Lancet; 2015 May; 385(9980):1853-62. PubMed ID: 25796459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful reversal of severe liver function impairment with Brentuximab vedotin in multiply relapsed/refractory classical Hodgkin lymphoma.
    Spathas N; Belia M; Giannikos T; Arapaki M; Efstathopoulou M; Tsourouflis G; Gainaru G; Asimakopoulos J; Tsaftaridis P; K Angelopoulou M; Plata E; Konstantopoulos K; P Vassilakopoulos T
    J BUON; 2019; 24(6):2483-2489. PubMed ID: 31983123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma.
    Picardi M; Della Pepa R; Giordano C; Pugliese N; Mortaruolo C; Trastulli F; Rascato MG; Cappuccio I; Raimondo M; Memoli M; Monteverde M; Mascolo M; Pane F
    Blood Adv; 2019 May; 3(9):1546-1552. PubMed ID: 31088808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of four cycles of Brentuximab Vedotin as consolidation after autologous peripheral stem cell transplantation in relapsed/refractory Hodgkin lymphoma.
    Kort J; Chidiac A; El Sayed R; Massoud R; Nehme R; Bazarbachi A; El-Cheikh J
    Leuk Lymphoma; 2020 Jul; 61(7):1732-1735. PubMed ID: 32090673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse.
    Moskowitz CH; Walewski J; Nademanee A; Masszi T; Agura E; Holowiecki J; Abidi MH; Chen AI; Stiff P; Viviani S; Bachanova V; Sureda A; McClendon T; Lee C; Lisano J; Sweetenham J
    Blood; 2018 Dec; 132(25):2639-2642. PubMed ID: 30266774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.
    Moretti M; Liberati AM; Rigacci L; Puccini B; Pulsoni A; Gini G; Galieni P; Fabbri A; Cantonetti M; Pavone V; Bolis S; Botto B; Renzi D; Falchi L
    Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):198-204. PubMed ID: 34690088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J; Ramchandren R; Santoro A; Paszkiewicz-Kozik E; Gasiorowski R; Johnson NA; Fogliatto LM; Goncalves I; de Oliveira JSR; Buccheri V; Perini GF; Goldschmidt N; Kriachok I; Dickinson M; Komarnicki M; McDonald A; Ozcan M; Sekiguchi N; Zhu Y; Nahar A; Marinello P; Zinzani PL;
    Lancet Oncol; 2021 Apr; 22(4):512-524. PubMed ID: 33721562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.
    Herrera AF; Palmer J; Martin P; Armenian S; Tsai NC; Kennedy N; Sahebi F; Cao T; Budde LE; Mei M; Siddiqi T; Popplewell L; Rosen ST; Kwak LW; Nademanee A; Forman SJ; Chen R
    Ann Oncol; 2018 Mar; 29(3):724-730. PubMed ID: 29272364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).
    Garcia-Sanz R; Sureda A; de la Cruz F; Canales M; Gonzalez AP; Pinana JL; Rodriguez A; Gutierrez A; Domingo-Domenech E; Sanchez-Gonzalez B; Rodriguez G; Lopez J; Moreno M; Rodriguez-Salazar MJ; Jimenez-Cabrera S; Caballero MD; Martinez C
    Ann Oncol; 2019 Apr; 30(4):612-620. PubMed ID: 30657848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation.
    Kaloyannidis P; Hertzberg M; Webb K; Zomas A; Schrover R; Hurst M; Jacob I; Nikoglou T; Connors JM
    Br J Haematol; 2020 Feb; 188(4):540-549. PubMed ID: 31588564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.